SEARCH

SEARCH BY CITATION

References

  • 1
    Stenson WF. Inflammatory mediators in inflammatory bowel disease. Curr Opin Gastroenterol 1994; 10: 3849.
  • 2
    Travis SPL & Jewel DP. Salicylates for ulcerative colitis—their mode of action. Pharmacol Ther 1994; 63: 13561.
  • 3
    Bratts R & Linden M. Cytokine modulation by glucocorticoids: mechanisms and actions in cellular studies. Aliment Pharmacol Ther 1996; 10: 8190.
  • 4
    Enns R & Sutherland L. Adverse events of medical therapy for treatment for inflammatory bowel disease. In: Campieri M, Bianchi-Porro G, Fiocchi C, Schölmerich J, eds. Clinical Challenges in Inflammatory Bowel Disease Diagnosis, Prognosis and Treatment. London: Kluwer Academic Publishers, 1998: 113–23.
  • 5
    Middleton E, Kandaswami C, Theoharides TC. The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer. Pharmacol Rev 2000; 52: 673751.
  • 6
    Sanchez de Medina F, Galvez J, Romero JA, Zarzuelo A. Effect of quercitrin on acute and chronic experimental colitis in the rat. J Pharmacol Exp Ther 1996; 278: 7719.
  • 7
    Cruz T, Galvez J, Ocete MA, Crespo ME, Sanchez de Medina F, Zarzuelo A. Oral administration of rutoside can ameliorate inflammatory bowel disease in rats. Life Sci 1998; 62: 68795.
  • 8
    Ocete MA, Galvez J, Crespo ME, et al. Effects of morin on an experimental model of acute colitis in rats. Pharmacology 1998; 57: 26170.
  • 9
    Crespo ME, Galvez J, Cruz T, Ocete MA, Zarzuelo A. Anti-inflammatory activity of diosmin and hesperidin in rat colitis induced by TNBS. Planta Med 1999; 65: 6513.
  • 10
    Kim YS, Son M, Ko JI, et al. Effect of DA-6034, a derivate of flavonoid, on experimental animal models of inflammatory bowel disease. Arch Pharm Res 1999; 22: 35460.
  • 11
    Smith C, Halliwell B, Aruoma OI. Protection by albumin against the pro-oxidant actions of phenolic dietary components. Food Chem Toxicol 1992; 30: 4839.
  • 12
    Mora A, Paya M, Rios JL, Alcaraz MJ. Structure–activity relationships of polymethoxyflavones and other flavonoids as inhibitors of non-enzymic lipid peroxidation. Biochem Pharmacol 1990; 40: 7937.
  • 13
    Wu TW, Zeng LH, Wu J, Fung KP. Morin hydrate is a plant-derived antioxidant-based hepatoprotector. Life Sci 1993; 53: 2138.
  • 14
    Wu TW, Zeng LH, Wu J, Fung KP. Morin: a wood pigment that protects three types of cells in the cardiovascular system against oxyradical damage. Biochem Pharmacol 1993; 47: 1099103.
  • 15
    Wu TW, Fung KP, Yang CC, Weisel RD. Antioxidant of human low density lipoprotein by morin hydrate. Life Sci 1995; 57: PL516.
  • 16
    Laughton MJ, Evans PJ, Moroney MA, Hoult JR, Halliwell B. Inhibition of mammalian 5-lipoxygenase and cyclo-oxygenase by flavonoids and phenolic dietary additives. Relationship to antioxidant activity and to iron ion-reducing ability. Biochem Pharmacol 1991; 42: 167381.
  • 17
    You MK, Jong HG, Kim HP. Inhibition of cyclooxygenase/lipoxygenase from human platelets by polyhydroxylated/methoxylated flavonoids isolated from medicinal plants. Arch Pharmacol Res 1999; 22: 1824.
  • 18
    Sharon P & Stenson WF. Enhanced synthesis of leukotriene B4 by colonic mucosa in inflammatory bowel disease. Gastroenterology 1984; 86: 45360.
  • 19
    Wallace JL. 5-Lipoxygenase: a rational target for therapy on inflammatory bowel disease? Trends Pharmacol Sci 1990; 11: 513.
  • 20
    Yamada T & Grisham MB. Pathogenesis of tissue injury: role of reactive metabolites of oxygen and nitrogen. In: Targan SR, Shanahan F, eds. Inflammatory Bowel Disease: From Bench to Bedside. Baltimore: Williams & Wilkins, 1994: 133–50.
  • 21
    Morris GP, Beck PL, Herridge W, Depew W, Szewczuk MR, Wallace JL. Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology 1989; 96: 795803.
  • 22
    Bell CJ, Gall DG, Wallace JL. Disruption of colonic electrolyte transport in experimental colitis. Am J Physiol 1995; 268: G62230.
  • 23
    Krawisz JE, Sharon P, Stenson WF. Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Assessment of inflammation in rat and hamster models. Gastroenterology 1984; 87: 134450.
  • 24
    Anderson ME. Determination of glutathione and glutathione disulfide in biological samples. Methods Enzymol 1985; 113: 54855.
  • 25
    Esterbauer H & Cheeseman KH. Determination of aldehydic lipid peroxidation products: malonaldehyde and 4-hydroxynonenal. Methods Enzymol 1990; 186: 40721.
  • 26
    Eastwood GL & Trier JS. Organ culture of human rectal mucosa. Gastroenterology 1973; 64: 37582.
  • 27
    Gaginella TS, Mascolo N, Izzo AA, Autore G, Capasso F. Nitric oxide as a mediator of bisacodyl and phenolphthalein laxative action: induction of nitric oxide synthase. J Pharmacol Exp Ther 1994; 270: 123945.
  • 28
    Boyde TRC & Rahmatullah M. Optimization of conditions for the colorimetric determination of citrulline, using diacetylmonoxime. Anal Biochem 1980; 107: 42431.
  • 29
    Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein–dye binding. Anal Biochem 1976; 72: 24854.
  • 30
    Mitchel JA, Sheng H, Förstermann U, Murad F. Characterization of nitric oxide synthases in non-adrenergic non-cholinergic nerve-containing tissue from the rat anococcygeus muscle. Br J Pharmacol 1991; 104: 28991.
  • 31
    Zea-Iriarte WL, Makiyama K, Goto S, et al. Impairment of antioxidants in colonic epithelial cells isolated from trinitrobenzene sulphonic acid-induced colitis in rats. Protective effect of rebamipide. Scand J Gastroenterol 1996; 31: 98592.
  • 32
    Galvez J, Garrido M, Merlos M, Torres MI, Zarzuelo A. Intestinal anti-inflammatory activity of UR-12746, a novel 5-ASA conjugate, on acute and chronic experimental colitis in the rat. Br J Pharmacol 2000; 130: 194959.
  • 33
    Veljaca M, Lesch CA, Pllana R, Sanchez B, Chan K, Guglietta A. BPC-15 reduces trinitrobenzene sulfonic-induced colonic damage in rats. J Pharmacol Exp Ther 1995; 272: 41722.
  • 34
    Hebda PA, Collins MA, Tharp MD. Mast cell and wound healing. Dermatol Clin 1993; 11: 68596.
  • 35
    Yamada T, Marshall S, Specian RD, Grisham MB. A comparative study of two models of experimental colitis in rats. Gastroenterology 1992; 102: 152434.
  • 36
    Kubes P, Grisham MB, Barrowman JA, Gaginella T, Granger DN. Leukocyte-induced vascular protein leakage in cat mesentery. Am J Physiol 1991; 261: H18729.
  • 37
    McKenzie SJ, Baker MS, Buffinton GD, Doe WF. Evidence of oxidant-induced injury to epithelial cells during inflammatory bowel disease. J Clin Invest 1996; 98: 13641.
  • 38
    Yue G, Sun FK, Dunn C, Yin K, Wong PYK. The 21-aminosteroid tirilazad mesylate can ameliorate inflammatory bowel disease in rats. J Pharmacol Exp Ther 1996; 276: 26570.
  • 39
    Rachmilewitz D, Karmeli F, Okon E, Bursztyn M. Experimental colitis is ameliorated by inhibition of nitric oxide synthase activity. Gut 1995; 37: 24755.
  • 40
    Hogaboam CM, Jacobson K, Collins SM, Blennerhassett MG. The selective beneficial effects of nitric oxide inhibition in experimental colitis. Am J Physiol 1995; 268: G67384.
  • 41
    Kimura H, Miura S, Shigematsu T, et al. Increased nitric oxide production and inducible nitric oxide synthase activity in colonic mucosa of patients with active ulcerative colitis and Crohn’s disease. Dig Dis Sci 1997; 42: 104754.
  • 42
    Moncada SR, Palmer MJ, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991; 43: 10942.
  • 43
    Kiss J, Lamarque D, Delchier JC, Whittle BJR. Time-dependent actions of nitric oxide synthase inhibition on colonic inflammation induced by trinitrobenzene sulphonic acid in rats. Eur J Pharmacol 1997; 336: 21924.
  • 44
    Lefer AM & Lefer DJ. Nitric oxide protects in intestinal inflammation. Am J Physiol 1999; 276: G5725.
  • 45
    Middleton SJ, Shorthouse M, Hunter JO. Increased nitric oxide synthesis in ulcerative colitis. Lancet 1993; 341: 4656.
  • 46
    Miller MJ, Sadowska-Krowicka SH, Chotinaruemol S, Kakkis JL, Clark DA. Amelioration of chronic ileitis by nitric oxide synthase inhibition. J Pharmacol Exp Ther 1993; 264: 116.
  • 47
    Soliman KF & Mazzio EA. In vitro attenuation of nitric oxide production in C6 astrocyte cell culture by various dietary compounds. Proc Exp Biol Med 1998; 218: 3907.
  • 48
    Raso GM, Meli R, Di Carlo G, Pacilio M, Di Carlo R. Inhibition of inducible nitric oxide synthase and cyclooxygenase-2 expression by flavonoids in macrophage J774A.1. Life Sci 2001; 68: 92131.
  • 49
    Ligumsky M, Simon PL, Karmeli F, Rachmilewitz D. Role of interleukin 1 in inflammatory bowel disease-enhanced production during active disease. Gut 1990; 31: 4636.
  • 50
    Gröttrup-Wolfers E, Moeller J, Karbach U, Müller-Lissner S, Endres S. Elevated cell-associated levels of interleukin 1β and interleukin 6 in inflamed mucosa of inflammatory bowel disease. Eur J Clin Invest 1996; 26: 11522.
  • 51
    Rachmilewitz D, Simon PL, Schwartz LW, Griswold DE, Fondacaro JD, Wasserman MA. Inflammatory mediators of experimental colitis in rats. Gastroenterology 1989; 97: 32637.
  • 52
    Morteau O, More J, Pons L, Bueno L. Platelet-activating factor and interleukin 1 are involved in colonic dysmotility in experimental colitis in rats. Gastroenterology 1993; 104: 4756.
  • 53
    Salzman AL, Denenberg AG, Ueta I, O'Connor M, Linn SC, Szabó C. Induction and activity of nitric oxide synthase in cultured human intestinal epithelial monolayers. Am J Physiol 1996; 270: G56573.